Literature DB >> 14586387

Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism.

Neal L Benowitz1, Margaret Peng, Peyton Jacob.   

Abstract

OBJECTIVES: Our objectives were to examine the effects of cigarette smoking on the disposition kinetics of chlorzoxazone and caffeine as probes of cytochrome p450 (CYP) 2E1, CYP1A2, xanthine oxidase, and N-acetyltransferase-2 activity and to test the hypothesis that carbon monoxide inhibits drug metabolism via these pathways.
METHODS: Twelve cigarette smokers were studied in 3 treatment conditions, each lasting 7 days, during which they smoked cigarettes, breathed carbon monoxide to achieve carboxyhemoglobin levels similar to those associated with cigarette smoking, or breathed air. In each treatment condition, subjects received oral chlorzoxazone (250 mg) and caffeine (250 mg) with measurement of disposition kinetics and urine metabolite profiles.
RESULTS: Compared with the air condition, cigarette smoking significantly induced the metabolism of chlorzoxazone (oral clearance, 5.9 +/- 1.5 mL x min(-1) x kg(-1) versus 4.8 +/- 1.0 mL x min(-1) x kg(-1), P <.005) and caffeine (2.0 +/- 0.8 mL x min(-1) x kg(-1) versus 1.5 +/- 0.7 mL x min(-1) x kg(-1), P <.001) but had no effect on caffeine urine metabolite ratios that reflect xanthine oxidase and N-acetyltransferase-2 activity. Considerable individual variability was noted in the extent of induction of metabolism by cigarette smoking, particularly as it affects chlorzoxazone (change in oral clearance ranged from -10% to +71%). Carbon monoxide had no effect on chlorzoxazone or caffeine metabolism or caffeine metabolic profile.
CONCLUSIONS: This study provides novel evidence that cigarette smoking accelerates chlorzoxazone metabolism, most likely reflecting induction of CYP2E1 activity, in humans. Induction of CYP2E1 activity by cigarette smoking could contribute to tobacco-induced cancer, alcohol-induced liver disease, and the risk of acetaminophen hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586387     DOI: 10.1016/j.clpt.2003.07.001

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

Review 1.  Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Authors:  G Sharma; S Vijayaraghavan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

2.  Effect of nicotine on cytochrome P450 1A2 activity.

Authors:  Janne Hukkanen; Peyton Jacob; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 3.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

4.  Coffee consumption and the risk of cancer in the Norwegian Women and Cancer (NOWAC) Study.

Authors:  Marko Lukic; Idlir Licaj; Eiliv Lund; Guri Skeie; Elisabete Weiderpass; Tonje Braaten
Journal:  Eur J Epidemiol       Date:  2016-03-24       Impact factor: 8.082

5.  Effects of long-term smoking on the activity and mRNA expression of CYP isozymes in rats.

Authors:  Xiao-Meng He; Ying Zhou; Ming-Zhen Xu; Yang Li; Hu-Qun Li; Wei-Yong Li
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

6.  Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.

Authors:  Janne Hukkanen; Peyton Jacob Iii; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

Review 7.  Effects of tobacco smoking and nicotine on cancer treatment.

Authors:  William P Petros; Islam R Younis; James N Ford; Scott A Weed
Journal:  Pharmacotherapy       Date:  2012-10       Impact factor: 4.705

8.  Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity.

Authors:  Lena Ernstgård; Margareta Warholm; Gunnar Johanson
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

9.  Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation.

Authors:  Harpal S Buttar; Timao Li; Nivedita Ravi
Journal:  Exp Clin Cardiol       Date:  2005

10.  Caffeine and risk of Parkinson's disease in a large cohort of men and women.

Authors:  Natalia Palacios; Xiang Gao; Marjorie L McCullough; Michael A Schwarzschild; Roma Shah; Susan Gapstur; Alberto Ascherio
Journal:  Mov Disord       Date:  2012-08-27       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.